Isomorphic Labs, the London-based AI drug-discovery company spun out of Google's DeepMind in 2021, has secured $5 billion in Series C funding as it pushes its most promising drug candidates toward human trials.
The funding round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor. All existing backers, including Alphabet's venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, participated in the round.
The investment represents a significant leap from Isomorphic's previous fundraising. Just six months earlier, in May, the company raised $2.1 billion in a Series B round. The latest funding signals growing confidence from major venture firms in the company's approach to using artificial intelligence for pharmaceutical development.
Building on AlphaFold's Legacy
Isomorphic Labs constructs an AI-powered drug-design engine that draws heavily from DeepMind's landmark AlphaFold system. AlphaFold, developed by Hassabis and DeepMind research director John Jumper, can predict the three-dimensional structure of proteins using only their genetic sequence as input. The pair were awarded the Nobel Prize in Chemistry for this breakthrough work in 2024.
The company's drug-design platform expands on this foundation by employing multiple simulation models that explore various domains of chemistry. These models work together to identify and design potential drug candidates that could interact effectively with target proteins involved in disease.
"We are exploring how the principles behind AlphaFold can be applied not just to understanding proteins, but to actively designing molecules that can modify their behavior," the company has stated in previous descriptions of its work.
From Design to Clinical Reality
The new capital will support Isomorphic's transition from computational drug design to actual clinical development. The company reports that its programs have produced positive preclinical results in oncology and immunology, two areas where new therapeutic approaches are urgently needed.
Isomorphic has already established partnerships with major pharmaceutical companies, including agreements with Eli Lilly, Novartis, and Johnson & Johnson. These collaborations provide the company with both financial support and access to the deep scientific expertise required to navigate the complex path from laboratory discovery to approved medicine.
The funding will also allow the company to expand into additional therapeutic areas beyond its current focus on cancer and immune disorders.
A Leadership Transition
The Series C marks Isomorphic's first major fundraising since founder Demis Hassabis stepped back from his role as head of DeepMind to concentrate on drug discovery. In the transition, Hassabis moved into a chairman position at DeepMind while continuing to lead Isomorphic as its chief executive officer.
This shift reflects the growing ambition within the Alphabet ecosystem to translate its AI research investments into real-world applications. DeepMind's scientific breakthroughs in protein structure prediction are now being directly commercialized through Isomorphic's drug development pipeline.
Bloomberg reported earlier this month that Isomorphic was seeking to raise funding at a valuation of approximately $50 billion. The company did not disclose its new valuation following the Series C close.
The Broader AI Drug Discovery Landscape
Isomorphic's successful fundraise comes as investors continue to pour money into AI-enabled drug development. Traditional pharmaceutical research is notoriously expensive and time-consuming, with estimates suggesting it costs over $1 billion and takes more than a decade to bring a single new drug to market.
AI platforms like Isomorphic's aim to accelerate this process by identifying promising drug candidates faster and reducing the failure rate in early-stage development. The company argues its approach can explore vastly more chemical possibilities than traditional methods, potentially shrinking the timeline for identifying viable drug candidates.
The pharmaceutical industry has taken notice. Major drugmakers have signed deals worth billions of dollars with AI drug-discovery companies across the sector, betting that machine learning could reshape how medicines are created.
What Comes Next
With $5 billion in fresh capital and multiple drug candidates advancing through its pipeline, Isomorphic Labs appears positioned to become a significant player in the next phase of AI-assisted drug development. The company will need to demonstrate that its computational approaches can translate into successful clinical outcomes, a milestone that has proven elusive for many in the field.
Watch for Isomorphic to announce specific clinical trial timelines for its lead programs in the coming months. The company's progress will be closely watched by both investors and the broader scientific community as they evaluate whether AI can truly transform pharmaceutical research.
Filed under: AI, TechNews, Startups, Biotech, DrugDiscovery, MachineLearning, Pharmaceuticals